Risk for disease progression, relapse, or death lower with modified R-CHOP regimen in which vincristine is replaced with polatuzumab vedotin<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Dec. 14, 2021 (HealthDay News) — For patients with diffuse large B-cell lymphoma (DLBCL), a modification of the regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), in which vincristine is replaced with polatuzumab vedotin (pola-R-CHP), results in a lower risk for disease progression, relapse, or death, according to a study published online Dec. 14 in the New England Journal of Medicine<\/em>. The research was published to coincide with the annual meeting of the American Society of Hematology, held from Dec. 11 to 14 in Atlanta.<\/p>\n Herv \u00a9 Tilly, M.D., from the University of Rouen in France, and colleagues conducted a double-blind international phase 3 trial to assess pola-R-CHP compared with standard R-CHOP. A total of 879 patients ages 18 to 80 years with previously untreated intermediate-risk or high-risk DLBCL were randomly assigned 1:1 to receive either pola-R-CHP or R-CHOP (440 and 439 patients, respectively), plus two cycles of rituximab alone.<\/p>\n The researchers found that after a median follow-up of 28.2 months, the percentage of patients surviving without progression was 76.7 and 70.2 percent at two years in the pola-R-CHP and R-CHOP groups, respectively (stratified hazard ratio for progression, relapse, or death, 0.73; 95 percent confidence interval, 0.57 to 0.95; P = 0.02). At two years, overall survival did not differ significantly between the groups (88.7 and 88.6 percent, respectively; hazard ratio for death, 0.94; 95 percent confidence interval, 0.65 to 1.37; P = 0.75). The groups had a similar safety profile.<\/p>\n “Among patients with DLBCL, first-line treatment with the pola-R-CHP combination evaluated in the current trial showed a progression-free survival benefit over the R-CHOP regimen at two years and had a similar safety profile,” the authors write.<\/p>\n The study was funded by F. Hoffmann-La Roche\/Genentech, the manufacturer of polatuzumab vedotin.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n